Lenkowsky Adam, EVP and Chief Commercial Officer, has engaged exclusively in selling activity involving Bristol-Myers Squibb (BMY) shares, according to SEC Form 4 filings. Over 28 reported transactions, all were dispositions, totaling $654,346 in aggregate value, with no recorded purchases. The most notable sales occurred on March 10, 2026, when Lenkowsky executed four separate transactions worth $129,038.98, $187,906.25, $54,898.69, and $49,968.03, all coded as "F" (payment of exercise price or tax liability). Earlier, on March 10, 2024, two additional sales were reported—a $174,010.65 transaction and a smaller $30,660.30 disposition—alongside multiple filings with zero-dollar values, likely representing option exercises or administrative adjustments.
The pattern indicates a consistent reduction in Lenkowsky’s BMY holdings, with all monetization events tied to derivative transactions rather than open-market sales. The absence of any buy transactions suggests a one-way flow of equity out of his portfolio, though the filings do not specify whether the sales were part of prearranged trading plans. The transactions are concentrated around annual March and November dates, possibly aligning with vesting schedules or tax-planning events. Given the lack of recent activity beyond March 2026, it remains unclear whether this disposition trend will continue or stabilize. The data reflects a clear, long-term divestment strategy limited solely to BMY, with no diversification into other securities.
AI-assisted summary